147 related articles for article (PubMed ID: 14565246)
61. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects.
Pourquier P; Pilon AA; Kohlhagen G; Mazumder A; Sharma A; Pommier Y
J Biol Chem; 1997 Oct; 272(42):26441-7. PubMed ID: 9334220
[TBL] [Abstract][Full Text] [Related]
62. Cyclopentenyl cytosine induces apoptosis and increases cytarabine-induced apoptosis in a T-lymphoblastic leukemic cell-line.
Verschuur AC; Brinkman J; Van Gennip AH; Leen R; Vet RJ; Evers LM; Voûte PA; Van Kuilenburg AB
Leuk Res; 2001 Oct; 25(10):891-900. PubMed ID: 11532523
[TBL] [Abstract][Full Text] [Related]
63. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
Gandhi V; Mineishi S; Huang P; Yang Y; Chubb S; Chapman AJ; Nowak BJ; Hertel LW; Plunkett W
Semin Oncol; 1995 Aug; 22(4 Suppl 11):61-7. PubMed ID: 7481847
[TBL] [Abstract][Full Text] [Related]
64. Position- and orientation-specific enhancement of topoisomerase I cleavage complexes by triplex DNA structures.
Antony S; Arimondo PB; Sun JS; Pommier Y
Nucleic Acids Res; 2004; 32(17):5163-73. PubMed ID: 15469908
[TBL] [Abstract][Full Text] [Related]
65. Structural Effects of Incorporation of 2'-Deoxy-2'2'-Difluorodeoxycytidine (Gemcitabine) in A- and B-Form Duplexes.
Cabrero C; Martín-Pintado N; Mazzini S; Gargallo R; Eritja R; Aviñó A; González C
Chemistry; 2021 May; 27(26):7351-7355. PubMed ID: 33772916
[TBL] [Abstract][Full Text] [Related]
66. Genotoxicity kinetics in murine normoblasts as an approach for the in vivo action of difluorodeoxycytidine.
Morales-Ramírez P; Vallarino-Kelly T; Cruz-Vallejo V
Cancer Chemother Pharmacol; 2017 May; 79(5):843-853. PubMed ID: 28324147
[TBL] [Abstract][Full Text] [Related]
67. One-electron oxidation of gemcitabine and analogs: mechanism of formation of C3' and C2' sugar radicals.
Adhikary A; Kumar A; Rayala R; Hindi RM; Adhikary A; Wnuk SF; Sevilla MD
J Am Chem Soc; 2014 Nov; 136(44):15646-53. PubMed ID: 25296262
[TBL] [Abstract][Full Text] [Related]
68. [Nucleoside kinases and new types of antitumor nucleosides].
Matsuda A
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1594-9. PubMed ID: 9309159
[TBL] [Abstract][Full Text] [Related]
69. Enhancement of DNA ligase I level by gemcitabine in human cancer cells.
Sun D; Urrabaz R; Kelly S; Nguyen M; Weitman S
Clin Cancer Res; 2002 Apr; 8(4):1189-95. PubMed ID: 11948132
[TBL] [Abstract][Full Text] [Related]
70. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
[TBL] [Abstract][Full Text] [Related]
71. Consequences of 2',2'-difluorodeoxycytidine (gemcitabine) on replicative DNA synthesis in intact HL-60 cells.
Ross DD; Cuddy DP
Semin Oncol; 1995 Aug; 22(4 Suppl 11):26-34. PubMed ID: 7481841
[TBL] [Abstract][Full Text] [Related]
72. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Hodge LS; Taub ME; Tracy TS
Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
[TBL] [Abstract][Full Text] [Related]
73. DNA polymerases as targets of anticancer nucleosides.
Miura S; Izuta S
Curr Drug Targets; 2004 Feb; 5(2):191-5. PubMed ID: 15011952
[TBL] [Abstract][Full Text] [Related]
74. Influence of gemcitabine (2',2'-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro.
Lech-Marańda E; Korycka A; Robak T
Eur J Haematol; 2000 Nov; 65(5):317-21. PubMed ID: 11092462
[TBL] [Abstract][Full Text] [Related]
75. New nucleoside analogs in the treatment of solid tumors.
Szafraniec SI; Stachnik KJ; Skierski JS
Acta Pol Pharm; 2004; 61(4):297-305. PubMed ID: 15575597
[TBL] [Abstract][Full Text] [Related]
76. Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes.
Cline SD; Osheroff N
J Biol Chem; 1999 Oct; 274(42):29740-3. PubMed ID: 10514448
[TBL] [Abstract][Full Text] [Related]
77. A possible role for topoisomerase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2'-deoxyuridine.
Goz B; Bastow KF
Mutat Res; 1997 Aug; 384(2):89-106. PubMed ID: 9298118
[TBL] [Abstract][Full Text] [Related]
78. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
[TBL] [Abstract][Full Text] [Related]
79. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.
Heinemann V; Schulz L; Issels RD; Plunkett W
Semin Oncol; 1995 Aug; 22(4 Suppl 11):11-8. PubMed ID: 7481839
[TBL] [Abstract][Full Text] [Related]
80. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
